The IPO trend remains robust in 2025, driven by strong retail investor interest and a shift from FPIs to the primary market.

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

According to Nasdaq’s data, the U.S. saw 179 non-SPAC IPOs in 2024 – the most since 2021, and a 40% increase over 2023 (127). By value raised (ex SPACs), it was an even better year, with value raised ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

Natural gas (NGH25) stocks have always been a way for investors to gain exposure to global energy markets. The energy sector ...

Shares of Nvidia, Broadcom, and ASML slump as China’s DeepSeek threatens the companies’ dominance in artificial intelligence, ...

There aren't too many investors better versed in technology than Phillipe Laffont. With a $6.5 billion net worth, according ...

Here's what's new in Bay Area biz news to start your workweek: tech stocks on wild ride, empty S.F. office buildings, copper ...

Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now set its financial goalposts, aiming to raise $114.4m from the initial public ...

A restaurant chain with more than 100 locations that's known for its sports-bar vibe and all-female waitstaff.

We recently compiled a list of the 10 High Growth Restaurant Stocks For 2025. In this article, we are going to take a look at ...

Weight-loss drug developer Metsera is targeting an up to $1.78 billion valuation in its initial public offering, the ARCH Venture Partners-backed biotech company said on Monday. New York City-based ...